TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pain in Adults With Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Non-specific inclusion criteria:~* intellectual quotient \>85~* consent form signed~Inclusion Criteria autism group :~* autism diagnosis (CIM 10) from multidisciplinary evaluation (ADI-r, ADOS)~* sibling without autism or developmental disorder~Non-specific Exclusion Criteria:~* chronic pain~* pregnancy, breast feeding~* consent form no signed~Exclusion criteria sibling and witness groups:~- diagnosis of autism or developmental disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- high functioning Autism (Type: EXPERIMENTAL): Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with high functioning Autism
- witness (Type: PLACEBO_COMPARATOR): Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with a witness

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Family Planning Ahead

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently pregnant~* Between 28 and 38 weeks' gestation at the time of enrollment~* Estimated due date in March, April, May, or June 2018~* 15 years or older~* Can read and write English~* Live in the United States~* Share a valid email address for study purposes~Exclusion Criteria~* Not currently pregnant~* Less than 28 weeks' or more than 38 weeks' gestation at the time of enrollment~* Estimated due date earlier than March 2018 or later than June 2018~* Under 15 years~* Can not read and write English~* Do not live in the United States~* Do not share a valid email address for study purposes

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patient Decision Aid (Type: EXPERIMENTAL): Birth Control After Pregnancy patient decision aid and supporting document
- Patient Information Leaflet (Type: ACTIVE_COMPARATOR): Postpartum Birth Control patient information leaflet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient with a primary renal cell carcinoma (RCC) tumor who is inoperable for technical (i.e surgical) or medical reasons~* Patient must be screened by a urologic surgeon to verify eligibility on the above basis~* Biopsy proof of RCC is preferred; however, in current practice the diagnosis is often clinical based on characteristic imaging. If there are compelling clinical reasons not to proceed with biopsy, the clinical diagnosis will suffice.~* Patient with metastases are eligible if in the opinion of the treating physicians the patient could benefit from treatment of the primary renal tumor.~* ECOG performance status 0-2~* Age ≥18 years~* Signed informed consent~Exclusion Criteria:~* Inadequate renal function, as measured by creatinine clearance calculated from 24 hour urine collection. Creatinine clearance values of at least 50 ml/min are required~* Prior attempt at curative treatment of this primary kidney tumor~* Inability to lie still for approximately 1 hour in immobilization device~* Presence of a connective tissue disorder other than rheumatoid arthritis.~* Pregnancy~* Inability to develop a radiation treatment plan that adheres to the dose constraints described below in Radiotherapy Treatment Planning section.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic Body Radiotherapy (SBRT) (Type: EXPERIMENTAL): Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of probable AD with supportive brain imaging documentation~* Have existing neuropsychiatric symptoms as defined by a score equal or greater than 10 on the NPI at screening, arising from item scores equal or greater than 2 (frequency X severity) on at least 2 domains.~* Has been on donepezil (stable dose of 5 mg or 10 mg) for at least four months, with no intent to change such for the duration of the study.~Exclusion Criteria:~* Demonstrate extreme agitation, physical aggression or violence to themselves, their caregiver, or others, and/or an inability to complete the ADAS-cog assessment at Screening.~* Have major structural brain disease other than Alzheimer's Disease~* Other severe acute or chronical medical or psychiatric condition or laboratory abnormality

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 mg QD of PF-05212377 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Executive Functions Rehabilitation in Premature Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: children~* born between 23-36.5 weeks of gestation~* age between 4 and 0 month -6 years and 11 months~* included in the V, Buzzi children's Hospital follow-up program~* resident no further than 20 km from the V. Buzzi Children's Hospital~* with WPPSI-III processing speed quotient of 91 or less~Exclusion Criteria:~* children affected by epilepsy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- training (Type: EXPERIMENTAL): children submitted to the Intendu training with motion based cognitive video games software
- no training (Type: NO_INTERVENTION): children not submitted to the training, entering the study as a control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Efficacy Study of T2000 in Myoclonus Dystonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should meet diagnostic criteria for M-D based on the following criteria:~  * myoclonus is the primary feature; focal or segmental dystonia of any severity may also be present~ * symptoms began by age 20~ * a familial pattern should be present~ * neurological history should not be suggestive of a different neurological condition~ * investigations such as imaging, EEG and evoked potential tests should be normal~* Patients will be eligible for this study if they are symptomatic on their current treatment, cannot tolerate current therapies, or are treatment naïve patients who have been explained treatment alternatives.~Exclusion Criteria:~* Patients adequately controlled without side effects on a current M-D treatment~* Current treatment with a barbiturate such as phenobarbital or primidone~* Pregnant patients or patients who may become pregnant during the study~* Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders~* Patients with seizure disorders~* Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin~* Patient with significant general medical or clinical laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): T2000

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any pediatric patient with an underlying diagnosis of a malignancy (excluding hematological malignancies like leukemias and lymphomas)~* ≥5% weight loss from diagnosis of primary malignancy (must be currently on chemotherapy and/or radiation therapy or scheduled to receive cancer therapy OR ≥5% weight loss following bone marrow transplant (autologous or allogeneic blood/bone marrow) and not actively receiving corticosteroid therapy~* Negative pregnancy test done =\< 7 days prior to registration for women of childbearing potential only~Exclusion Criteria:~* Receiving tube feedings or parenteral nutrition~* Evidence of ascites~* Current (within the past 28 days) or planned treatment with adrenal steroids (short-term use of dexamethasone around days of intravenous chemotherapy is allowed for protection against emesis), androgens, progestational agents, or appetite stimulants (e.g., dronabinol)~* Known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting (\> 5 episodes/week)~* History of unresectable brain tumor or cancer metastatic to the brain~* History of thromboembolic disease~* Insulin-requiring diabetes~* Congestive heart failure and/or uncontrolled hypertension~* Anticoagulation~* Previous history of thrombosis (personal and immediate family)~* Concurrent corticosteroid therapy (except as an antiemetic)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
- Arm B (Type: ACTIVE_COMPARATOR): Patients have clinical observation for weight loss and gain for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impedancemetry in Patients Monitored for Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient over 18 years and under 80 years~* Patients who have been diagnosed with PAH (group 1 PH according to the Nice 2013 classification) or post-embolic pulmonary hypertension (group 4 PH) under medical treatment;~* HTP incident or prevalent less than 6 months~* Patient coming for follow-up or emergency consultation or hospitalization with a clinical examination and a walking test~* Patient affiliated to a health insurance scheme~* Patient having signed informed consent~Exclusion Criteria:~* Subjects under juridical protections or tutelage measure~* pregnant or lactating woman~* pulmonary hypertension du to cardiac pathology, chronic respiratory disease, or uncertain determinism.~* pulmonary hypertension of group 4 treated surgically or endoscopically.~* pulmonary hypertension incident or prevail for 6 months or more~* contraindication to impedancemetry~* inability to perform a walking test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- cardiac impedancemetry (Type: EXPERIMENTAL): Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for PH. Patients are included via the competence center of the PHP of the Midi Pyrenees region. The cardiac output is measured by impedance measurement at rest and during the walking test. The NO / CO coupled transfer measurement is performed at rest. The physician performing the consultation will not know the results of the IPC and these results will not influence the subsequent management.~The patient will be followed for 18 months as part of the research.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Performance of an e-Health System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients presenting all the following characteristics are eligible for inclusion:~1. Adult (\>18 yrs), male or female~2. Presenting at least two chronic diseases among the following three: chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), diabetes~3. Having been hospitalized in the CHANGE or in any other medical care center (hospital or private clinic) for acute decompensation of CHF or exacerbation of COPD at least once during the 12 months prior to inclusion~4. Able to speak and understand French to a satisfactory standard~5. Having a phone land line~6. Capable of understanding and accepting the study constraints~7. Having signed a written informed consent after a full explanation of the study by the investigator prior to inclusion~Exclusion Criteria:~Patients presenting any one of the following characteristics are not eligible for inclusion:~1. Pregnant or breast-feeding woman~2. Institutionalized~3. Having a life expectancy of less than 3 months~4. Receiving or having received chemotherapy or radiotherapy for cancer within the past 6 months~5. Undergoing dialysis for chronic renal insufficiency~6. Presenting a condition likely to hamper accomplishment of the study procedures, such as chronic alcoholism, drug or solvent addiction, uncontrolled psychiatric disease or severe cognitive deficiency~7. Not covered by French Social Security~8. Participating or having participated in another interventional trial within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- medical device intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \< 65 years with hematologic malignancies needing stem cell transplant but do not have HLA-matched sibling donor. Patients with the following diagnosis will be included:~  * AML in first or subsequent complete or partial remissions~ * ALL in first or subsequent complete or partial remissions~ * CLL in second remission or more advanced disease~ * CML who has failed tyrosine kinase inhibitors~ * Hodgkin's disease who relapse after autologous transplant~ * Non-Hodgkin's lymphoma who relapse after autologous transplant or NK-cell lymphoma in CR1~ * Aplastic anemia patients~ * Multiple myeloma in second remission or moer advanced disease, including those who have failed an autologous transplant~ * Myelodysplastic syndrome in first or subsequent complete or partial remission~* Patients must have 6/6, 5/6 or 4/6 molecular matches from unrelated UCB donors. Matching will be done for A, B, and DR. Matching at DR will be confirmed by molecular typing.~* Patients must be documented to be HIV negative. Screening must have been performed within previous 6 months.~* Patients must be able to give written consent.~Exclusion Criteria:~* Patient is excluded if all of the Inclusion criteria above isn't met.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin for Circadian Sleep Disorders in the Blind

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* blindness for at least one year, verified by an ophthalmologic exam~* ability to comply with the requirements of the experimental protocol~* competency to sign informed consent~Exclusion criteria (as determined by medical history and/or physical examination):~* abnormal heart, liver or kidney function~* a current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual~* possibly external demands that limit the ability to maintain a regular schedule (e.g., night shift work)~* sexually active female subjects of child-bearing potential will be asked to avoid pregnancy using accepted methods and will be notified that the effects of melatonin on a fetus are not known (we will ask subjects monthly if they are pregnant or trying to become pregnant)~* if a subject reports she is pregnant or is trying to become pregnant anytime during her study participation, any study medications (melatonin or placebo) will be immediately withdrawn and the subject will be excluded from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Baseline (Type: NO_INTERVENTION): None
- Melatonin (Type: EXPERIMENTAL): Subjects will be administered melatonin.
- Light (Type: EXPERIMENTAL): None
- Regular Sleep Schedule (Type: EXPERIMENTAL): None
- Longitudinal Monitoring (Type: NO_INTERVENTION): Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Development of a NIPTT for Detecting Copy Number Variations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is female~* Subject is 18 years of age or older~* Subject is pregnant at no less than 10 weeks and no more than 36 weeks gestation~* Subject provides a signed and dated informed consent~* Subject has a current pregnancy in which the fetus is determined to have a chormosomal abnormality of interest (microinsertions, microdeletions and other CNVs) as determined by microarray analysis of fetal cellular material obtained by IP~Exclusion Criteria:~* Subject has experienced fetal demise in the current pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues